The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
So has the UK govt ordered more innova tests because they had given the deal the green light weeks ago and accepted that mologic weren't part of govt sovereign test plans, or had they ordered more useless Chinese tests prior to this agreement and then gave the go ahead for a foreign takeover as mologic were now not deemed a key UK industry as we have lots of bin fodder on the way? Are they going to use this as an excuse to delay manufacture of a UK developed test until 2022 as not enough capacity? Wouldn't be surprised if the take over was allowed and then someone had an 'oh sh*t' moment and realised they've just given away UK capacity and had to order more innova tests while they work out who to blame.
If this was under NDA then either Al found out about it same time as us and we're not involved (so no RNS imo), or he's been way ahead of everyone and we're already a key party, and hopefully confirm in about 8 hours time . Either way, I'll think we'll need that foreign manufacturing capacity
If avacta were solely a covid play, with nothing else in the pipeline, licencing the affimer tech from elsewhere and needing govt orders to survive, I might be worried. But they're not.
Instead as a side project they've designed, developed and produced a test based on their affimer tech. They've jumped through hoops, changing requirements, battled govt corruption and bureaucracy and brought a test to market. This isn't any old test, but a test based on new technology, not only has this first generation test proved more accurate in real world use than any currently available, but can be cheaper, adaptable to future strains at speeds only achieved by expensive and logistically difficult PCR and highly scalable. No other test manufacturer can compete for accuracy, whether its antibody based, or aptamer based (where even mologic have thrown the towel in). Avacta are quite simply in a league of their own. Other nanobody tech is years away from commercial use, ours can be delivered to your door in early August.
The diagnostic industry is about to enter a new dawn, affimer tech right now has been proven to work, and work better than anything else on the market. Pharmas will be well aware, they'll be in discussion on licensing for their own use. Selling a few tests will be nice, heck a gov contract will be lovely, assuming they pay, but the real winner, is showing just how damn good and versatile affimers are. Biotechs would kill to have an industry redefining tech in their Arsenal, we have at least 3.
Could this hit £1 this week? Who gives a ****. Just sit back, put your feet up and know that in 24 - 36 months you'll be chuckling to yourself at how the gamblers and doom merchants of the board tried to make you sell, and you'll be sat on more money than you thought possible.
Turd of a day, but people who had stop losses set deserve to be mugged imo, this share is better off without the panicky gamblers 'invested' who learned nothing from vaccinegate.
I'm in no rush, I've got over 15 years to wait for this to hit £25+. Or does that mean my pension is accessible 'shortly'?
Roll on next week when Julie might admit defeat at losing the post-it note and do a password recovery on the RNS logging site.
... But we'll see
https://mobile.twitter.com/InnovaScandal/status/1412024494139527171
https://www.portugalresident.com/government-to-start-funding-quickie-antigen-tests-four-per-month/
Just need to get on their approved list, no doubt other EU countries to offer similar.
Performed at pharmacies, and may be used for this covid passport scheme to some countries
Why doesnt' Al open a franchise in China and call it "Ha-wak-ta lice silences", we'd be a shoe in for UK Govt contracts then
ODX look utterly f**ked if this is true, someone at or near the top is determined to not give the UK consortium any money.
I've just changed my exit price from £50 to £500.
Even if this takes 5 years to come to market, its over another 5 years of sales before patent expires.
Any patent experts here - the patent for affimers expires in a decade or so but can avacta still retain ownership of individual affimer designs so other companies have to start from scratch (and in effect 4-5 years behind from the outset) or license them in perpetually
I'm not a shorter, and I'd definitely class him as a ramper. But if I was balls deep having bought when the SP peaked and now looking at a huge loss I'd be ramping like mad constantly too, so I don't blame him. SP will come good, just wait for the dispute to be settled, which it will, just may take a few months. In the mean time, just keep buying when you can, as at these levels the risk is pretty damn low imo. Just need patience, which PIs find difficult (including me)
Every man and his dog has an LFT out, and the professional one is pretty average compared to the competition and targeting our PCR customers will canabilise sales. The saliva test is the interesting one given avacta scrapped the idea, but its not available yet. I'm hopeful it comes the govt chosen test given its the only one that hits the 'desired' requirement. Otherwise will the sacrifice in accuracy appease those that want ease of use? Maybe it could see introduction into schools. Why no word on who the partner is?
What CT are those s & s values for? If >30 then pretty damn impressive, if <25 then a bit p!ss poor.
Both companies are aware of each other as they say with bojo back in september last year.
Avacta working with mologic who are suing Govt, working with abingdon who are suing dhsc, maybe work with nova, who are going to sue dhsc, so yeah, I see a perfect fit. Maybe we should team up with lawyers4u and put this affimer business on hold
1) Dispute no where near settled
2) Future £100m+ DHSC contracts extremely unlikely imo
3) GM has yet to demonstrate how we're going to be making £50m+ a year in a world without covid. That may be some time off yet, but markets like certainty
In the short - medium term pathflow might help with the push back to £4+.
I'm now hoping for a buy out, an offer of £6 and I'd bite their arm off
This antigen LFT better be damn good. UK market is dead, US and Europe will be key. The dispute likely to drag on for many months if we're not even at the court stage yet. 'Good' thing about non payment, is nova can legally apply interest of 8% above base rate. Hopefully by early next year it will be sorted one way or the other, but I'd imagine it's put the brakes on plans for now. Frustrating.
So £7m avr a month sales, without DHSC, still impressive. I hope GM is now pimping us out to every pharma and vc out there.
Agree. I see zero risk now, SP could easily double over next 12-18 months.
Wouldn't be surprised if some pharma needing a diagnostic division was circling now, I reckon they're waiting for the LFT news, they've had clarification on dispute sums. Would also explain lack of acquisitions so far.
I'm down over £30k this month, surely one of my stocks will go green this summer. This is probably the most likely. My ideal news tomorrow will be dispute settled, at least £75m of the £150 accounted for, private sales £30m this quarter, LFT news. Hello £7 by Friday
Worst outcome "still think we can assert contractual rights ", nothing on the LFT and £5m or less private sales , finish red. Limp along for 6 months and hope for a buy out.